Daraxonrasib in Previously Treated Advanced <em>RAS</em>-Mutated Pancreatic Cancer

This study investigates the safety and efficacy of daraxonrasib, a multiselective RAS inhibitor, in patients with previously treated advanced RAS-mutated pancreatic ductal adenocarcinoma (PDAC). The results indicate that while 96% of patients experienced treatment-related adverse events, daraxonrasib demonstrated antitumor activity, with objective response rates of 35% in patients with RAS G12 mutations and 29% in those with other RAS mutations. The findings suggest potential benefits of daraxonrasib in this challenging patient population, warranting further investigation.